Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Class A common stock, par value $0.00001 per share
-
Shares outstanding
-
114M
-
Number of holders
-
270
-
Total 13F shares, excl. options
-
104M
-
Shares change
-
+845K
-
Total reported value, excl. options
-
$1.5B
-
Value change
-
-$41.5M
-
Put/Call ratio
-
1.73
-
Number of buys
-
129
-
Number of sells
-
-138
-
Price
-
$14.36
Significant Holders of 10x Genomics, Inc. - Class A common stock, par value $0.00001 per share (TXG) as of Q4 2024
326 filings reported holding TXG - 10x Genomics, Inc. - Class A common stock, par value $0.00001 per share as of Q4 2024.
10x Genomics, Inc. - Class A common stock, par value $0.00001 per share (TXG) has 270 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 104M shares
of 114M outstanding shares and own 91.34% of the company stock.
Largest 10 shareholders include FMR LLC (13.5M shares), ARK Investment Management LLC (11.9M shares), VANGUARD GROUP INC (10.9M shares), BlackRock, Inc. (6.77M shares), Nikko Asset Management Americas, Inc. (5.71M shares), Sumitomo Mitsui Trust Group, Inc. (5.71M shares), MORGAN STANLEY (3.93M shares), RA CAPITAL MANAGEMENT, L.P. (3.28M shares), UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.12M shares), and CITADEL ADVISORS LLC (2.01M shares).
This table shows the top 270 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.